Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.
Brentjens
Renier
R
Yeh
Raymond
R
Bernal
Yvette
Y
Riviere
Isabelle
I
Sadelain
Michel
M
D000368:Aged; D018941:Antigens, CD19 / Q000235:genetics / Q000276:immunology; D018106:CD28 Antigens / Q000235:genetics / Q000276:immunology; D017321:Clinical Trials, Phase I as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D017809:Fatal Outcome; D018390:Gene Targeting; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000628:therapy*; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation*
D018941:Antigens, CD19; D018106:CD28 Antigens; D011993:Recombinant Fusion Proteins; D003520:Cyclophosphamide